Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Sarah Orfanos, Ibrahim El Husseini, Thomas Nahass, Jared Radbel, Sabiha Hussain. Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space. ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020

Member's Comments

No comment yet.

Related content which might interest you: The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019 Year: 2019 Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 Soluble urokinase plasminogen activator receptor (suPAR) is associated with COPD readmission and mortality Source: International Congress 2019 – Long-term lung function: from early birth to adulthood Year: 2019 LATE-BREAKING ABSTRACT: Molecular mechanisms of plasminogen activator inhibitor-1 elevation in COPD sputum Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease Year: 2012 Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018 Year: 2019 Plasminogen activator inhibitor-1 (PAI-1) mutations of extended half-life time inhibit angiogenic properties of human lung microvascular endothelial cells (HMVEC-L) Source: Eur Respir J 2003; 22: Suppl. 45, 225s Year: 2003 Human lung microvascular endothelial cells (HMVEC-L) angiogenic activity is inhibited by stable plasminogen activator inhibitor-1 (PAI-1) mutants via urokinase-dependent pathway Source: Annual Congress 2004 - Lung development and cancer Year: 2004 Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010